FDA-Approved Medications to Treat Tardive Dyskinesia

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.

Original languageEnglish (US)
JournalThe Journal of clinical psychiatry
Volume81
Issue number1
DOIs
StatePublished - Dec 17 2019

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'FDA-Approved Medications to Treat Tardive Dyskinesia'. Together they form a unique fingerprint.

  • Cite this